<DOC>
	<DOCNO>NCT00949442</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority insulin glargine insulin NPH ( Neutral Protamin Hagedornon ) change HbA1c baseline end treatment period . Secondary Objective : To compare treatment group : - Plasma glucose ( fast , nocturnal ) time , - Changes baseline HbA1c time , - Percentage patient reach target HbA1c &lt; 7 &lt; 6.5 , - Use prandial insulin rescue medication month 6 , - Incidence rate hypoglycemia ( symptomatic diurnal nocturnal , asymptomatic severe ) , - Daily dose insulin , - Change body weight baseline , - Evolution 8-point plasma-glucose ( PG ) profile , - Overall safety , - Patient report outcome ( treatment satisfaction ) .</brief_summary>
	<brief_title>Lantus Versus NPH : Comparison Insulin Naive People Not Adequately Controlled With Least One Oral Anti Diabetics ( OAD ) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Insulinnaïve type 2 diabetes mellitus Type 2 diabetes mellitus diagnose least 1 year Treated least one OAD ( Metformin [ daily dose least 1000mg ] , Sulfonylurea , glinides alphaglucosidase inhibitor ) stable dose least 3 month . HbA1c &gt; = 7.0 % &lt; = 10.5 % BMI &lt; 40 kg/m² Ability willingness perform plasma glucose monitor use sponsorprovided glucose meter patient diary home Informed consent obtain write enrolment study Willingness ability comply study protocol Exclusion criterion : Treatment GLP1 agonists DPPIV inhibitor 3 month prior study entry Treatment TZD monotherapy Diabetes mellitus Type 2 ( e.g . secondary pancreatic disorder , drug chemical agent intake ... ) Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study ( optic fundus examination perform within 2 year prior study entry ) Impaired renal function : serum creatinine &gt; =1.5 mg/dL ( &gt; = 133µmol/L ) &gt; = 1.4 mg/dL ( &gt; = 124 µmol/L ) men woman , respectively History sensitivity study drug drug similar chemical structure Impaired hepatic function ( ALT and/or AST &gt; 3 x upper limit normal range ) Pregnant lactate woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) , Treatment systemic corticosteroid within 3 month prior study entry likelihood require treatment study permit . Treatment investigational product 30 day prior visit 1 Alcohol drug abuse last year Presence condition ( medical , psychological , social geographical ) , current anticipate Investigator feel would compromise patient 's safety limit patient successful participation study ( include night shift worker ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>